Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) shares saw unusually-high trading volume on Tuesday . Approximately 662,369 shares changed hands during trading, an increase of 161% from the previous session’s volume of 254,005 shares.The stock last traded at $7.15 and had previously closed at $6.95.

ITEK has been the topic of a number of recent research reports. Canaccord Genuity reissued a “buy” rating on shares of Inotek Pharmaceuticals Corp. in a research report on Saturday, May 14th. Piper Jaffray Cos. reissued a “buy” rating on shares of Inotek Pharmaceuticals Corp. in a research report on Thursday, May 12th.

The stock’s market cap is $188.78 million. The firm has a 50 day moving average price of $7.57 and a 200-day moving average price of $8.06.

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) last issued its earnings results on Wednesday, August 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.07. On average, analysts anticipate that Inotek Pharmaceuticals Corp. will post ($1.42) EPS for the current year.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.